A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors.

Inclusion Criteria:

1. Male or female subjects greater than or equal to 18 years of age.

2. Subjects who have provided written informed consent to participate in the study.

3. Subjects with documented evidence of cancer with clinically measurable or evaluable
disease. Cancer can be recurrent after primary treatment with surgery, radiation
therapy and/or chemotherapy and may include those subjects for whom no standard or
curative therapy exists.

4. Measurable tumor by imaging (CT per RECIST criteria). unless an established tumor
marker exists which can be used for assessment of response in the absence of
measurable disease (i.e., PSA in prostate cancer or CA 125 in ovarian cancer).

5. No recent myocardial infarction (within 3 months) or serious intercurrent
cardiovascular disease (any event that requires evaluation by a cardiologist, with a
definitive cardiac disease diagnosed) Subjects with a history of severe cardiac
disease should have had a recent consultation with a cardiologist documenting that
there are no new findings.

6. No overt cardiac metastasis.

7. Negative pregnancy test if in women of childbearing potential within one week of
starting therapy.

8. ECOG Performance Status of 0, 1, or 2.

9. Absolute neutrophil greater than or equal to 1500 cells/uL, hemoglobin greater than
or equal to 9 gm/dl, platelets greater than or equal to 100,000/uL, ALT/AST less than
or equal to 3 x ULN (upper limit of the normal range) unless involved with tumor then
less than 5 x ULN, bilirubin less than or equal to 1.5 x ULN, creatinine less than or
equal to 1.5 x ULN, normal creatinine clearance greater than 60 mL/min and a normal
serum bicarbonate. Normal is defined by local laboratory specifications.

Exclusion Criteria:

Subjects meeting any of the following criteria will not be considered eligible for
participation in the study:

1. Women who are pregnant or breast-feeding (women of child-bearing potential must have
a negative serum pregnancy test within one week of entering the study).

2. Women of child-bearing potential who are unwilling to use two medically acceptable
forms of contraception during the course of the study (surgical sterilization,
approved hormonal contraceptives, or barrier method with spermicide).

3. Subjects unable to comply with the study requirements.

4. Subjects with a known sensitivity to any of the study medication components.

5. Subjects exhibiting any of the following: a marked baseline prolongation of QT/QTc
interval (repeated demonstration of a calculated QTc interval >450), a history of
additional risk factors for TdP (e.g. heart failure, hypokalemia, family history of
long QT Syndrome), and subjects unable or unwilling to refrain from using medications
that are known to prolong the QT/QTc ratio during the course of the study. Subjects
having recently taken such medications must have five half-lives off medication
before participation.

6. Subjects with an existing port not compatible with the terameprocol formulation.